{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T05:04:56Z","timestamp":1789275896674,"version":"build-2803163510"},"reference-count":27,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005627","name":"Thrasher Research Foundation","doi-asserted-by":"publisher","award":["1502"],"award-info":[{"award-number":["1502"]}],"id":[{"id":"10.13039\/100005627","id-type":"DOI","asserted-by":"publisher"}]},{"award":["1502"],"award-info":[{"award-number":["1502"]}],"id":[{"id":"https:\/\/ror.org\/03hnrwx04","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["315982\/Z\/24\/Z"],"award-info":[{"award-number":["315982\/Z\/24\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220211"],"award-info":[{"award-number":["220211"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"award":["315982\/Z\/24\/Z"],"award-info":[{"award-number":["315982\/Z\/24\/Z"]}],"id":[{"id":"https:\/\/ror.org\/029chgv08","id-type":"ROR","asserted-by":"publisher"}]},{"award":["220211"],"award-info":[{"award-number":["220211"]}],"id":[{"id":"https:\/\/ror.org\/029chgv08","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: Scabies is a disease that disproportionately affects young children. Oral ivermectin is a mainstay of scabies therapy, yet children &lt;15 kg are excluded due to insufficient safety data and the lack of age-appropriate formulations. To address this gap, we developed CHILD-IVITAB, a 1 mg ivermectin orodispersible tablet based on the Template Inverted Particle technology, which enables rapid disintegration and intrinsic taste masking in a mechanically robust tablet. Methods: We report the pharmaceutical characterization of CHILD-IVITAB tablets. The EPIC-15 trial (NCT06404333) was a randomized clinical trial administering CHILD-IVITAB to children weighing 5 to &lt;15 kg with uncomplicated scabies in Brazil. Acceptability was assessed at two administrations (D0, D7) using the ClinSearch Acceptability Score Test (CAST\u00ae), wherein CHILD-IVITAB was compared to a reference dataset. Results: The 40 mg tablets had a tensile strength of 1.87 \u00b1 0.16 MPa, and met Ph. Eur. requirements for uniformity of mass and dosage units. CHILD-IVITAB tablets disintegrated in vitro in 18.3 \u00b1 1.1 s and released &gt;50% of the dose within 1 min in artificial saliva. Thirteen children were enrolled in the trial. The full dose was taken in 100% of the 26 evaluations, 73% of administrations elicited a neutral or positive reaction, and no dosage form alteration, food\/drink co-administration, or extra device was required. The barycenter of all evaluations fell within the positive zone of the CAST\u00ae framework. Conclusions: These results support CHILD-IVITAB as a child-friendly ivermectin formulation suitable for children 5 to &lt;15 kg, a population currently excluded from ivermectin treatment and prevention programs.<\/jats:p>","DOI":"10.3390\/pharmaceutics18091147","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:51:37Z","timestamp":1789123897000},"page":"1147","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CHILD-IVITAB, a Novel Orodispersible Ivermectin Formulation\u2014Pharmaceutical Evaluation and Clinical Acceptability in Children &lt;15 kg"],"prefix":"10.3390","volume":"18","author":[{"given":"Diell","family":"Aliu","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Basel, 4001 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3643-5500","authenticated-orcid":false,"given":"Thibault","family":"Vallet","sequence":"additional","affiliation":[{"name":"ClinSearch, 92240 Malakoff, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1748-5676","authenticated-orcid":false,"given":"J\u00f6rg","family":"Huwyler","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Basel, 4001 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7028-2774","authenticated-orcid":false,"given":"Maxim","family":"Puchkov","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Basel, 4001 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenna","family":"Pereira de Souza","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus 69040-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Freitas Medeiros","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus 69040-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuelton","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus 69040-000, Brazil"},{"name":"Escola Superior de Ci\u00eancias da Sa\u00fade, Universidade do Estado do Amazonas, Manaus 69065-001, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5723-9977","authenticated-orcid":false,"given":"Jacqueline de Almeida Gon\u00e7alves","family":"Sachett","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus 69040-000, Brazil"},{"name":"Escola Superior de Ci\u00eancias da Sa\u00fade, Universidade do Estado do Amazonas, Manaus 69065-001, Brazil"},{"name":"Funda\u00e7\u00e3o Hospitalar Alfredo da Matta, Manaus 69065-130, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9167-0189","authenticated-orcid":false,"given":"Fabrice","family":"Ruiz","sequence":"additional","affiliation":[{"name":"ClinSearch, 92240 Malakoff, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Buettcher","sequence":"additional","affiliation":[{"name":"University Children\u2019s Hospital Basel (UKBB), 4031 Basel, Switzerland"},{"name":"Faculty of Health Sciences and Medicine, University of Lucerne, 6002 Lucerne, Switzerland"},{"name":"Paediatric Infectious Diseases Unit, Children\u2019s Hospital of Central Switzerland (Kidz), 6004 Lucerne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-1228","authenticated-orcid":false,"given":"Marc","family":"Pfister","sequence":"additional","affiliation":[{"name":"University Children\u2019s Hospital Basel (UKBB), 4031 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz von","family":"Seidlein","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Bangkok 10400, Thailand"},{"name":"Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Tarning","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Bangkok 10400, Thailand"},{"name":"Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4807-9681","authenticated-orcid":false,"given":"Kevin C.","family":"Kobylinski","sequence":"additional","affiliation":[{"name":"Mahidol Oxford Tropical Medicine Research Unit, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0140-6736(19)31136-5","article-title":"The public health control of scabies: Priorities for research and action","volume":"394","author":"Engelman","year":"2019","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Li, J., Liu, Z., and Xia, X. (2024). The disability-adjusted life years (DALYs), prevalence and incidence of scabies, 1990-2021: A systematic analysis from the Global Burden of Disease Study 2021. PLoS Neglected Trop. Dis., 18.","DOI":"10.1371\/journal.pntd.0012775"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1500987","article-title":"Mass Drug Administration for Scabies Control in a Population with Endemic Disease","volume":"373","author":"Romani","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","first-page":"Cd012994","article-title":"Ivermectin and permethrin for treating scabies","volume":"4","author":"Rosumeck","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_5","unstructured":"(2025, September 10). Mectizan Donation Program 2024 Mectizan Donation Program Annual Highlights: Legacy\u2014Honoring the Visionaries to Secure the Future. Available online: https:\/\/mectizan.org\/wp-content\/uploads\/2025\/05\/MDP_AH24_Eng_Interactive_F2.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Jittamala, P., Monteiro, W., Smit, M., Pedrique, B., Specht, S., Chaccour, C., Dard, C., Del Giudice, P., Khieu, V., and Maruani, A. (2021). A systematic review of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?. PLoS Neglected Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009144"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/bjd.18369","article-title":"Ivermectin safety in infants and children under 15 kg treated for scabies: A multicentric observational study","volume":"182","author":"Levy","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s00105-021-04806-4","article-title":"Development of an ivermectin-containing syrup as an extemporaneous preparation for treatment of scabies in children","volume":"72","author":"Wohlrab","year":"2021","journal-title":"Hautarzt"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2303333","DOI":"10.1002\/adfm.202303333","article-title":"Calcium Phosphate Microcapsules as Multifunctional Drug Delivery Devices","volume":"33","author":"Kost","year":"2023","journal-title":"Adv. Funct. Mater."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e114785","DOI":"10.1016\/j.ejpb.2025.114785","article-title":"Drug loading mechanism of hollow hydroxyapatite microcapsules","volume":"214","author":"Kost","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/jcph.2462","article-title":"Novel Patient-Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use","volume":"64","author":"Dao","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Golhen, K., Buettcher, M., Huwyler, J., van den Anker, J., Gotta, V., Dao, K., Rothuizen, L., Kobylinski, K., and Pfister, M. (2024). Pharmacometrics to Evaluate Dosing of the Patient-Friendly Ivermectin CHILD-IVITAB in Children \u226515 kg and <15 kg. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16091186"},{"key":"ref_13","unstructured":"European Medicines Agency (2013). Guideline on Pharmaceutical Development of Medicines for Paediatric Use, European Medicines Agency."},{"key":"ref_14","unstructured":"European Medicines Agency (2023). Letter of Support for an Acceptability Score Test in Relative Acceptability Testing for Oral Medicines in Children Under 12 Years of Age, European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/other\/letter-support-acceptability-score-test-relative-acceptability-testing-oral-medicines-children-under-12-years-age_en.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/jphp.12547","article-title":"Standardized method to assess medicines\u2019 acceptability: Focus on paediatric population","volume":"69","author":"Ruiz","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/jps.2600590523","article-title":"Determination of tablet strength by the diametral-compression test","volume":"59","author":"Fell","year":"1970","journal-title":"J. Pharm. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s40265-014-0297-2","article-title":"Patient-centred pharmaceutical design to improve acceptability of medicines: Similarities and differences in paediatric and geriatric populations","volume":"74","author":"Liu","year":"2014","journal-title":"Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.powtec.2011.12.060","article-title":"Determination of the tensile strength of elongated tablets","volume":"238","author":"Pitt","year":"2013","journal-title":"Powder Technol."},{"key":"ref_19","unstructured":"United States Pharmacopeial Convention (2024). The United States Pharmacopeia and National Formulary, USP-NF."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/bjd.18943","article-title":"The 2020 International Alliance for the Control of Scabies Consensus Criteria for the Diagnosis of Scabies","volume":"183","author":"Engelman","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v025.i01","article-title":"FactoMineR: An R package for multivariate analysis","volume":"25","author":"Le","year":"2008","journal-title":"J. Stat. Softw."},{"key":"ref_22","unstructured":"Food and Drug Administration (2008). Guidance for Industry; Orally Disintegrating Tablets, Center for Drug Evaluation and Research (CDER)."},{"key":"ref_23","unstructured":"European Directory for the Quality of Medicines & Healthcare (2026). The European Pharmacopeia, European Directory for the Quality of Medicines & Healthcare. [12th ed.]."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/jps.21512","article-title":"Hydrodynamic, mass transfer, and dissolution effects induced by tablet location during dissolution testing","volume":"98","author":"Bai","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/psp4.12950","article-title":"PBPK modeling of ivermectin-Considerations for the purpose of developing alternative routes to optimize its safety profile","volume":"12","author":"Wesche","year":"2023","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Desai, N., Redfearn, A., MacLeod, G., Tuleu, C., Hanson, B., and Orlu, M. (2020). How Do Orodispersible Tablets Behave in an In Vitro Oral Cavity Model: A Pilot Study. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12070651"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1473-3099(25)00472-4","article-title":"Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: A single-blind, randomised, controlled, dose-ranging, phase 2 trial","volume":"26","author":"Sprecher","year":"2026","journal-title":"Lancet Infect. Dis."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1147\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:16:21Z","timestamp":1789272981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pharmaceutics18091147"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18091147","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}